Your session is about to expire
← Back to Search
Experimental Group for Pancreatic Cancer
Study Summary
This trial will test a new cancer drug, sotorasib, to see if it is safe and effective when combined with standard chemotherapy for treating pancreatic cancer that has progressed after first-line treatment.
- Pancreatic Cancer
- KRAS Mutation
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has enrollment begun for this particular clinical experiment?
"Affirmative, the information on clinicaltrials.gov confirms that this examination is recruiting participants. It was first released on September 13th 2022 and updated most recently on September 22nd 2022. 59 people need to be sourced from a single medical institution for participation in the trial."
How many participants have registered for this research initiative?
"Affirmative. Per the details hosted on clinicaltrials.gov, this medical trial is actively seeking out patients to join in their research endeavour; first posted on September 13th 2022 and last updated a few days later. They are looking for 59 volunteers from one single location."
Share this study with friends
Copy Link
Messenger